Valuation: Orexo AB

Market Cap 527M 54.39M 47.73M 44.45M 40.88M 76.64M 5.2B 77.95M 206M 2.58B 204M 200M 8.9B P/E 2026 *
-1.44x
P/E 2027 * -2.07x
Enterprise Value 422M 43.56M 38.23M 35.6M 32.74M 61.38M 4.16B 62.43M 165M 2.06B 164M 160M 7.13B EV / Sales 2026 *
22.2x
EV / Sales 2027 * 14x
Free-Float
70.1%
Yield 2026 *
-
Yield 2027 * -
1 week-3.21%
Current month-37.08%
1 month-38.37%
3 months-21.76%
6 months-50.17%
Current year-49.83%
1 week 14.42
Extreme 14.42
16.48
1 month 14.04
Extreme 14.04
25.35
Current year 14.04
Extreme 14.04
36
1 year 14.04
Extreme 14.04
43.4
3 years 9.18
Extreme 9.18
43.4
5 years 8.44
Extreme 8.44
43.4
10 years 8.44
Extreme 8.44
87.9
Manager TitleAgeSince
Chief Executive Officer 54 04/02/2013
Director of Finance/CFO 59 31/08/2022
Chief Tech/Sci/R&D Officer - 30/09/2024
Director TitleAgeSince
Director/Board Member 64 31/12/2001
Director/Board Member 70 10/04/2019
Director/Board Member 62 31/03/2022
Date Insider Type Main position Quantity % Market Cap.
04/09/25 Buy

Chief Executive Officer

6 0.0000%
04/09/25 Free

Chief Executive Officer

1,393 0.0040%
03/09/25 Buy 1 0.0000%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-3.21%-29.44%-13.52% 54.21M
+0.81%+4.40%+56.82%+23.96% 323B
+1.76%+7.45%+27.60%-10.04% 70.11B
+2.41%+6.16%+44.54%+91.12% 9.66B
+1.68%+2.87%+4.63%-0.50% 8.51B
-2.93%+2.45%-20.66%-2.69% 4.37B
-3.73%-3.89%-9.31%+1.86% 3.75B
-1.81%+1.58%-41.23%+7.12% 3.66B
+1.60%-0.29%+42.86%+56.90% 2.73B
-0.87%-4.54%-7.97%-10.77% 2.11B
Average -0.10%+0.74%+6.78%+14.34% 42.79B
Weighted average by Cap. +0.92%+5.20%+48.09%+18.84%

Financials

2026 *2027 *
Net sales 19M 1.96M 1.72M 1.6M 1.47M 2.76M 187M 2.81M 7.44M 92.85M 7.36M 7.2M 321M 27.5M 2.84M 2.49M 2.32M 2.13M 4M 271M 4.07M 10.76M 134M 10.65M 10.42M 464M
Net income -375M -38.68M -33.94M -31.61M -29.07M -54.5M -3.7B -55.43M -147M -1.83B -145M -142M -6.33B -270M -27.9M -24.48M -22.8M -20.97M -39.31M -2.67B -39.99M -106M -1.32B -105M -102M -4.57B
Net Debt -105M -10.83M -9.5M -8.85M -8.14M -15.26M -1.03B -15.52M -41.1M -513M -40.66M -39.78M -1.77B -143M -14.75M -12.94M -12.05M -11.09M -20.78M -1.41B -21.14M -55.97M -699M -55.37M -54.18M -2.41B
Logo Orexo AB
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.
Employees
61
Date Price Change Volume
28/07/26 SEK 15.10 0.00% 21,941
27/07/26 SEK 15.10 -0.92% 51,217
24/07/26 SEK 15.24 +0.26% 15,640
23/07/26 SEK 15.20 -1.17% 41,617
22/07/26 SEK 15.38 -1.41% 45,380
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB

Quarterly revenue - Rate of surprise